Trailing-twelve-month (TTM) revenue is $2.71 Billion with a year-over-year growth of +37.82%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $592,183,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-07 |
| Q4 FY2025Period ended 2025-12-31 | $665,500,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-27 |
| Q1 FY2026Period ended 2026-03-31 | $696,644,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-08 |
| Q2 FY2026Period ended 2026-06-30 | $752,750,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-07 |
| TTM revenue | $2,707,077,000 |
Current P/S: $58,768,275,250 market capitalization ÷ $2,707,077,000 TTM revenue = 21.71x.
Market capitalization source: FMP quote. Quote observed 2026-10-02T20:00:00.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $752.75M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-02T22:35:57.718Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-02.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Genetic testing services | N/A | N/A | N/A | $18M | N/A | N/A |
| Licensing and other | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Americas Excluding Us | $3M | N/A | N/A | N/A | N/A | N/A |
| Americas, excluding U.S. | N/A | $4M |
$2.71B
$2.71 Billion
+37.82%
vs. $1.96B a year ago (TTM)
+39.92%
5 Year compound annual growth rate
1 Year
+37.82%
3 Year
+42.72%
5 Year
+39.92%
10 Year
+29.03%
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $2.31B | +$609.20M | +35.90% |
| 2024 | $1.70B | +$614.34M | +56.75% |
| 2023 | $1.08B | +$262.35M | +31.99% |
| 2022 | $820.22M | +$194.74M | +31.13% |
| 2021 | $625.49M | +$234.48M | +59.97% |
| 2020 |
TTM Growth
+37.82%
3-Year CAGR
+42.72%
5-Year CAGR
+39.92%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-02T22:35:57.718Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-02.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $23M |
| $14M |
| $12M |
| $10M |
| Licensing And Other | $24M | N/A | N/A | N/A | N/A | N/A |
|---|
| Oncology products | N/A | N/A | N/A | $19M | N/A | N/A |
|---|
| Product | $367M | $567M | $797M | $1.1B | $1.7B | $2.3B |
|---|
| $4M |
| $5M |
| $7M |
| $9M |
| Asia Pacific and Other | N/A | $10M | $14M | $7M | $9M | $8M |
|---|
| Europe Middle East India And Africa | $14M | N/A | N/A | N/A | N/A | N/A |
|---|
| Europe, Middle East, India, Africa | N/A | N/A | $17M | $23M | $24M | N/A |
|---|
| Europe, Middle East, India, and Africa | N/A | $20M | N/A | N/A | N/A | $24M |
|---|
| Other Geographic Areas | $8M | N/A | N/A | N/A | N/A | N/A |
|---|
| U | $366M | N/A | N/A | N/A | N/A | N/A |
|---|
| United States | N/A | $591M | $786M | $1.0B | $1.7B | $2.3B |
|---|
| $391.00M |
| +$88.68M |
| +29.33% |
| 2019 | $302.33M | +$44.67M | +17.34% |
| 2018 | $257.65M | +$46.72M | +22.15% |
| 2017 | $210.94M | ($6.13M) | (2.83%) |
| 2016 | $217.07M | +$26.72M | +14.04% |
